Publications by authors named "Chahr-Eddine Hadjseyd"
Purpose Of Review: Chronic kidney disease (CKD) is highly prevalent in patients with heart failure and reduced ejection fraction (HFrEF), representing a major factor of adverse outcomes. In clinical practice, it is one of the main reasons for not initiating, not titrating, and even withdrawing efficient heart failure drug therapies in patients.
Recent Findings: Despite limited data, studies show that HFrEF therapies maintain their benefits on cardiovascular outcomes in patients with CKD.
Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey.
Charles Fauvel Guillaume Bonnet Wilfried Mullens Clara Ines Saldarriaga Giraldo Anja Zupan Mežnar Chahr-Eddine Hadjseyd
Eur J Heart Fail
February 2023
Article Synopsis
- Recent guidelines suggest starting four key heart failure (HF) medications for patients with reduced ejection fraction (HFrEF) at once, but there's uncertainty about how cardiologists view this approach compared to HF specialists.
- A survey with 615 cardiologists globally revealed that most prefer a traditional sequential treatment method, starting with ACE inhibitors or other recommended therapies.
- Although many agree that beginning all four medications during initial hospitalization is doable, there's still a preference for the classic approach, indicating a need for research to alter treatment practices.